Penny Stocks To Watch: Advanced Cell Technology (ACTC)

Shares in the penny stock of Advanced Cell Technology Inc. (OTC: ACTC) closed up 2.34% at $0.083 as investors await the April 26th shareholder meeting. ACTC traded less than 1/3 of the 3m average volume on Friday as the penny stock continued its decline from its Ytd high back in January. Regardless, ACTC deserves to be on the penny stocks ...

Continue Reading →
0

Shares in Penny Stock Advanced Cell Technology (ACTC) Plunge

Shares in stem cell penny stock Advanced Cell Technology, Inc. (OTCBB: ACTC.OB) dropped -1.12% on in its last trading session to close at $0.0880. ACTC’s total outstanding common stock is outrageous large at 2,029,049,544, almost all of which are floated in the OTC market, which the company has recently addressed in hopes of gaining the apporval of the penny stock’s shareholders in an ...

Continue Reading →
0

OTC Stocks: Advanced Cell Technology (ACTC) Going Nasdaq?

If anyone thinks that investing in penny stocks takes nerves of steel, then one must turn their attention to one of the great penny stocks, Advanced Cell Technology, Inc. (OTCBB: ACTC), to experience some real high risk, high reward potential. Until recently, only those day trading penny stocks and investors who know how to buy penny stocks had ever heard of this hot penny stock. Today ...

Continue Reading →
0

4 Stem Cell Stocks To Watch: ASTM, BTX, ACTC, NBS

February was a tough month for biotech stocks researching stem cells for the treatment and cure of diseases. TickerSpy’s Stem Cell Stocks Index (RXSTM) has slipped nearly 13% since early February being outperformed by the S&P 500 by close to 17% during that time.

Four particular stem cell stocks, all cheap stocks under 5 including 2 penny stocks, should ...

Continue Reading →
0

Advanced Cell Technology (ACTC) Advancing Phase I/II Trials

One of the leaders in volume daily for penny stocks, Advanced Cell Technology, Inc. (OTC: ACTC), a regenerative medicine working with stem cells, looks forward to conducting  Phase I/II clinical trial for Stargardt’s Macular Dystrophy (SMD) after the Wills Eye Institute in Philadelphia received institutional review board (IRB) approval. SMD is a ...

Continue Reading →
0

Top 10 Penny Stocks To Watch Monday, February 13

North Springs Resources Corp. (OTC: NSRS) was undoubtedly the hottest penny stock traded for the week ended February 10. When the mining exploration company closed on a high Monday at $1.48 only to open higher Tuesday at $1.72 on news of sample surveys from its Imperial and Goldstar properties.  Tuesday’s close ...

Continue Reading →
0

ACTC Announces Aberdeen Royal Infirmary in Scotland as Additional Site for Phase 1/2 Clinical Trial

Advanced Cell Technology, Inc. (OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Aberdeen Royal Infirmary, the largest of the Grampian University Hospitals in Scotland, has been confirmed as a site for its Phase 1/2 human clinical trial for Stargardt’s Macular Dystrophy (SMD) using retinal ...

Continue Reading →
0

ACTC, Advanced Cell Technology Insider Transactions

On Wednesday, January 25, 2012, Advanced Cell Technology, Inc. (OTCBB: ACTC) Chief Science Officer Robert Lanza filed SEC Form 4, as required for insider trading, indicating that he sold 7.7 million shares for $1.5 million, ending with 26.0 million shares after that sale.

http://www.sec.gov/Archives/edgar/data/1140098/000114420412003966/xslF345X03/v300304_4.xml

Continue Reading →

0

ACTC: Additional Patient with Stargardt’s Disease Has Undergone Embryonic Stem Cell Transplantation

Advanced Cell Technology, Inc. (OTCBB: ACTC), a leader in the field of regenerative medicine, announced today the dosing of an additional patient in its Phase 1/2 trial for Stargardt’s macular dystrophy using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

The patient was treated on Tuesday (Jan. 24) by Steven Schwartz, M.D., Ahmanson Professor of ...

Continue Reading →
0

Update: ACTC Advanced Cell Technology Stem Cell Research

“Be fearful when others are greedy, and be greedy when others are fearful.” – Warren Buffett

Advanced Cell Technology, Inc. (OTCBB:ACTC), announced via Businesswire today that Phase 1/2 clinical data published in The Lancet as an early online publication demonstrate the safety of ACT’s human embryonic ...

Continue Reading →
0
Page 2 of 3 123